Search research articles
Contact Us
Filters
Showing results (21-30 of 167) with videos related to
Page
of 17
Sort By:
Drug News & Perspectives
|
April 22, 2006
Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis
Heidelinde Jakel, Jamila Fruchart-Najib, Jean-Charles Fruchart
Current Atherosclerosis Reports
|
August 18, 2005
Pleiotropic effects of fibrates
Giulia Chinetti-Gbaguidi, Jean Charles Fruchart, Bart Staels
Current Opinion in Pharmacology
|
March 23, 2005
Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy
Giulia Chinetti-Gbaguidi, Jean-Charles Fruchart, Bart Staels
Circulation Research
|
May 15, 2004
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells
Nikolaus Marx, Hélène Duez, Jean-Charles Fruchart, et al.
Journal De La Societe De Biologie
|
July 24, 2002
[Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control]
Virginie Bocher, Giulia Chinetti, Jean-Charles Fruchart, et al.
Journal of the American College of Nutrition
|
June 14, 2003
Postprandial leptin response to carbohydrate and fat meals in obese women
Monique Romon, Pascal Lebel, Jean-Charles Fruchart, et al.
Trends in Endocrinology and Metabolism: TEM
|
September 8, 2004
Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes
Olivier Barbier, Coralie Fontaine, Jean-Charles Fruchart, et al.
The Journal of Clinical Investigation
|
March 3, 2006
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis
Philippe Lefebvre, Giulia Chinetti, Jean-Charles Fruchart, et al.
Expert Opinion on Emerging Drugs
|
August 31, 2006
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis
Benoit Pourcet, Jean-Charles Fruchart, Bart Staels, et al.
Current Atherosclerosis Reports
|
July 17, 2020
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib
Page
of 17
Search research articles
Search
Showing results (21-30 of 167) with videos related to
Sort By:
Page
of 17
Drug News & Perspectives
|
April 22, 2006
Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis
Heidelinde Jakel, Jamila Fruchart-Najib, Jean-Charles Fruchart
Current Atherosclerosis Reports
|
August 18, 2005
Pleiotropic effects of fibrates
Giulia Chinetti-Gbaguidi, Jean Charles Fruchart, Bart Staels
Current Opinion in Pharmacology
|
March 23, 2005
Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy
Giulia Chinetti-Gbaguidi, Jean-Charles Fruchart, Bart Staels
Circulation Research
|
May 15, 2004
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells
Nikolaus Marx, Hélène Duez, Jean-Charles Fruchart, et al.
Journal De La Societe De Biologie
|
July 24, 2002
[Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control]
Virginie Bocher, Giulia Chinetti, Jean-Charles Fruchart, et al.
Journal of the American College of Nutrition
|
June 14, 2003
Postprandial leptin response to carbohydrate and fat meals in obese women
Monique Romon, Pascal Lebel, Jean-Charles Fruchart, et al.
Trends in Endocrinology and Metabolism: TEM
|
September 8, 2004
Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes
Olivier Barbier, Coralie Fontaine, Jean-Charles Fruchart, et al.
The Journal of Clinical Investigation
|
March 3, 2006
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis
Philippe Lefebvre, Giulia Chinetti, Jean-Charles Fruchart, et al.
Expert Opinion on Emerging Drugs
|
August 31, 2006
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis
Benoit Pourcet, Jean-Charles Fruchart, Bart Staels, et al.
Current Atherosclerosis Reports
|
July 17, 2020
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib
Page
of 17